353 related articles for article (PubMed ID: 27609791)
21. Italian Multicenter Study on Accuracy of
Cistaro A; Cassalia L; Ferrara C; Quartuccio N; Evangelista L; Bianchi M; Fagioli F; Bisi G; Baldari S; Zanella A; Pillon M; Zucchetta P; Burei M; Sala A; Guerra L; Guglielmo P; Burnelli R; Panareo S; Scalorbi F; Rambaldi I; Piccardo A; Garaventa A; Familiari D; Fornito MC; Lopci E; Mascarin M; Altini C; Ferrari C; Perillo T; Santoro N; Borsatti E; Rubini G
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e267-e273. PubMed ID: 29739722
[TBL] [Abstract][Full Text] [Related]
22. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
23. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
24.
Sibille L; Seifert R; Avramovic N; Vehren T; Spottiswoode B; Zuehlsdorff S; Schäfers M
Radiology; 2020 Feb; 294(2):445-452. PubMed ID: 31821122
[TBL] [Abstract][Full Text] [Related]
25. 11C-Methionine Positron Emission Tomography/Computed Tomography Versus 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Evaluation of Residual or Recurrent World Health Organization Grades II and III Meningioma After Treatment.
Tomura N; Saginoya T; Goto H
J Comput Assist Tomogr; 2018; 42(4):517-521. PubMed ID: 29613985
[TBL] [Abstract][Full Text] [Related]
26. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of incidental [18 F]FDG uptake in the gastrointestinal tract on PET/CT imaging: a retrospective cohort study.
Shmidt E; Nehra V; Lowe V; Oxentenko AS
BMC Gastroenterol; 2016 Oct; 16(1):125. PubMed ID: 27716085
[TBL] [Abstract][Full Text] [Related]
28. PET/CT findings for tumors in the base of the skull: comparison of 18 F-FDG with 11 C-methionine.
Tomura N; Mizuno Y; Saginoya T
Acta Radiol; 2016 Mar; 57(3):325-32. PubMed ID: 25795702
[TBL] [Abstract][Full Text] [Related]
29. Metabolic assessment of intracranial tuberculomas using 11C-methionine and 18F-FDG PET/CT.
D'Souza MM; Sharma R; Jaimini A; Panwar P; Bansal A; Tripathi M; Varshney R; Pandey S; Mondal A
Nucl Med Commun; 2012 Apr; 33(4):408-14. PubMed ID: 22301451
[TBL] [Abstract][Full Text] [Related]
30.
Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
[TBL] [Abstract][Full Text] [Related]
31. Relationship between the uptake of
Watanabe Y; Kurihara H; Itami J; Sasaki R; Arai Y; Sugimura K
Radiat Oncol; 2017 Jan; 12(1):17. PubMed ID: 28088230
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
33.
Morales-Lozano MI; Rodriguez-Otero P; Sancho L; Nuñez-Cordoba JM; Prieto E; Marcos-Jubilar M; Rosales JJ; Alfonso A; Guillen EF; San-Miguel J; Garcia-Velloso MJ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077292
[TBL] [Abstract][Full Text] [Related]
34. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
35. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
[TBL] [Abstract][Full Text] [Related]
36. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
37. Determination of brain tumor recurrence using
Yamaguchi S; Hirata K; Okamoto M; Shimosegawa E; Hatazawa J; Hirayama R; Kagawa N; Kishima H; Oriuchi N; Fujii M; Kobayashi K; Kobayashi H; Terasaka S; Nishijima KI; Kuge Y; Ito YM; Nishihara H; Tamaki N; Shiga T
Cancer Sci; 2021 Oct; 112(10):4246-4256. PubMed ID: 34061417
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of bone marrow
Lee JW; Lee SC; Kim HJ; Lee SM
Hell J Nucl Med; 2017; 20(1):17-25. PubMed ID: 28315904
[TBL] [Abstract][Full Text] [Related]
39. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
[TBL] [Abstract][Full Text] [Related]
40. PET/computed tomography and lymphoma.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
